177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study.

Magdalena MilevaCamille Van BogaertGwennaëlle MarinRachele DanieliCarlos ArtigasHugo LevillainLieveke AmeyeLoubna Taraji-SchiltzKonstantinos StathopoulosZéna WimanaAlain HendliszPatrick FlamenIoannis Karfis

Published in: Clinical nuclear medicine (2024)

This study confirms the safety profile of 177 Lu-DOTATATE PRRT in patients with GEP-NETs irrespective of the dosimetry of organs at risk. Kidney, bone marrow, and spleen dosimetry measures were not associated with renal or hematological toxicity.

Keyphrases

neuroendocrine tumors
bone marrow
mesenchymal stem cells
oxidative stress
electronic health record
monte carlo